CancerNCT06927050
Visual Communication: Digital Tool to Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers
A study testing Visual Communication Tool in people with Cancer, run by NYU Langone Health at 1 site in United States.
Trial summary
This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience. Read more about this study
- Who is it for?
- Ages 18 to 100 years
- Conditions the study is for
- Cancer
- What is being tested?
- Visual Communication Tool
- Type of treatment
- Pill or oral medicine, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 86 participants
- Where
- 1 siteUnited States
- Study dates
- 21 Apr 2025to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 100 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients:
- Patients seen in consultation from 12/1/2024-6/1/2025
- Patients aged 18 years to 100 years old
- Patients with a malignancy of breast or head and neck
- English speaking patients
- Patients being treated with definitive intent
Show all 15Show fewer
- Patients treated at NYU Langone Health for their malignancy
- Willing and able to provide consent
- Caregivers:
- Any adult caregiver(s) (aged 18 years to 100 years old) to a patient who fulfills the inclusion and exclusion criteria above.
- Willing and able to provide consent
- Providers:
- Doctors and nurse practitioners in medical oncology and radiation oncology, and in the ear nose throat (ENT) department.
- Willing and able to provide consent
- aged 18 years to 100 years old
Who cannot join
- Patients:
- Patients with any other site of disease other than listed above
- Non-English-speaking patients, as the tool is currently available in English only. Translation into additional languages such as Spanish and Russian is currently in process.
- Patient unable to complete the survey portion of the study independently
- Caregivers:
- Unable to complete the survey portion of the study independently
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
NYU Langone Health
New York, New York, 10016
About this study
Official title: Visual Communication: Can a Digital Tool Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers?
This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.
- Conditions
- Cancer
- Being tested
- Visual Communication Tool
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Visual Communication ToolBehavioural
Also called MyCareGorithm
MyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet.
| Study group | Role | What they receive |
|---|---|---|
| Patients (and caregivers) recently diagnosed with cancer | Experimental | Enrolled patients will receive a tool during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. Following the encounter, a survey will be provided.
If patients are accompanied by a caregiver(s), they will also receive a survey. Receives: Behavioral: Visual Communication Tool |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of "Satisfied" Patients
Patients will take a 9-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; patients with 6 or more "Yes" answers out of 9 questions are defined as "Satisfied" patients.
Measured: Day 0
Secondary outcomes (2)
Percentage of "Satisfied" Caregivers
Caregivers of patients (if applicable) will take a 10-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; caregivers with 7 or more "Yes" answers out of 10 questions will be defined as "Satisfied" caregivers.
Measured: Day 0
Percentage of "Satisfied" Providers
For each patient encountered, providers will take a 5-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; a provider with 3 or more "Yes" answers out of 5 questions for a patient will be defined as a "Satisfied" provider for this patient.
Measured: Day 0
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2025
- Study start21 Apr 2025
- Primary completion1 Apr 2026 (estimated)
- Study completion1 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CancerStudies of the same condition, open and under way.
- More trials run by NYU Langone HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 86 participants (estimated)
Sponsor and investigators
- Lead sponsor
- NYU Langone Health
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jason Domogauer, MD, PhD, Principal investigator, NYU Langone Health
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06927050
- Sponsor's protocol ID
- 24-01870
- Status last verified
- Feb 2026
- First submitted
- 8 Apr 2025
- Last updated
- 25 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jason.Domogauer@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Study at a glance
From the registry record, last updated by the sponsor on 25 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Visual Communication: Can a Digital Tool Improve the Understanding of Treatment Options for Patients With Cancer and Increase Satisfaction of the Overall Experience for Patients, Caregivers, and Providers?
- ClinicalTrials.gov ID
- NCT06927050
- Acronym / sponsor ID
- 24-01870
- Conditions
- Cancer
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 86 participants (estimated)
- Lead sponsor
- NYU Langone HealthUniversity, hospital or other
- Study start
- 21 Apr 2025 (actual)
- Primary completion
- 1 Apr 2026 (estimated)
- Study completion
- 1 Apr 2026 (estimated)
- First posted
- 15 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This is a study in patients with newly diagnosed cancer to prospectively evaluate the feasibility of integration of a visual communication tool for patients/caregivers/providers by determining whether such a tool can increase overall satisfaction with the patient experience.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients (and caregivers) recently diagnosed with cancer | Experimental | Behavioral: Visual Communication ToolEnrolled patients will receive a tool during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. Following the encounter, a survey will be provided. If patients are accompanied by a caregiver(s), they will also receive a survey. |
Who may qualify
- Ages
- 18 to 100 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (15 listed)
- Patients seen in consultation from 12/1/2024-6/1/2025
- Patients aged 18 years to 100 years old
- Patients with a malignancy of breast or head and neck
- English speaking patients
- Patients being treated with definitive intent
Key exclusion criteria (6 listed)
- Patients with any other site of disease other than listed above
- Non-English-speaking patients, as the tool is currently available in English only. Translation into additional languages such as Spanish and Russian is currently in process.
- Patient unable to complete the survey portion of the study independently
- Unable to complete the survey portion of the study independently
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Visual Communication ToolAlso: MyCareGorithmMyCareGorithm will be used during the patient consultation encounter to explain their disease location and stage, role of radiation, logistics of radiation treatment delivery and sequencing of treatment. MyCareGorithm is an online educational tool that will be displayed to the patient via iPad or Microsoft tablet. | Behavioural | Patients (and caregivers) recently diagnosed with cancer |
Primary outcome
Percentage of "Satisfied" Patients
Time frame: Day 0
Patients will take a 9-item survey assessing satisfaction with the intervention. Each item is rated as "Yes" or "No." The total score is the sum of "Yes" responses; patients with 6 or more "Yes" answers out of 9 questions are defined as "Satisfied" patients.
2 secondary outcomes
Percentage of "Satisfied" Caregivers
Time frame: Day 0
Percentage of "Satisfied" Providers
Time frame: Day 0
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Feb 2026.
- Individual participant dataSharing planned: Yes. The de-identified participant data from the final research dataset will be shared upon reasonable request beginning 9 to 36 months after publication or as required by a condition of awards or supporting agreements, provided the requesting investigator executes a data use agreement with NYU Langone Health. This instance of data sharing will also require separate IRB review as well as review from NYU Langone's Data Sharing Strategy Board (DSSB). Requests should be directed to: Jason.Domogauer@nyulangone.org. The protocol and statistical analysis plan will be posted on Clinicaltrials.gov only as required by federal regulation or supporting awards and agreements.
Related trials for Cancer
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Active, not recruitingPhase 1/2
Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma
Low Grade Glioma, Recurrent Childhood Pilocytic Astrocytoma
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
Recruiting
Methylation Profiling in Self-Samples for Identification of (Epi)Genetic Biomarkers for Gynecological Cancers
Gynaecological Cancers, Ovarian Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jason Domogauer, MD, PhD principal investigator
NYU Langone Health
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Visual Communication Tool in people with Cancer, run by NYU Langone Health at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 25 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jason Domogauer, MD, PhD ((212) 501-5003, Jason.Domogauer@nyulangone.org), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of "Satisfied" Patients (time frame: Day 0). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Feb 2026.